Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die. According to Centers for Disease Control and Prevention (CDC), 14,000 - 15,000 Americans had ALS in 2016.
The classification of Amyotrophic Lateral Sclerosis (ALS) Treatment includes Riluzole, Edaravone (Radicava) and Other and the proportion of Edaravone (Radicava) in 2017 is about 67.7%, Radicava is approved in Japan and Korea in 2015, and through the FDA in 2017.
In 2018, the global Amyotrophic Lateral Sclerosis (ALS) Treatment market size was 240 million US$ and it is expected to reach 380 million US$ by the end of 2025, with a CAGR of 6.9% during 2019-2025.
This report focuses on the global Amyotrophic Lateral Sclerosis (ALS) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Amyotrophic Lateral Sclerosis (ALS) Treatment development in United States, Europe and China.
The key players covered in this study
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Market segment by Type, the product can be split into
Riluzole
Edaravone (Radicava)
Other
Market segment by Application, split into
Hospital
Drugs Store
Other
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Amyotrophic Lateral Sclerosis (ALS) Treatment status, future forecast, growth opportunity, key market and key players.
To present the Amyotrophic Lateral Sclerosis (ALS) Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Amyotrophic Lateral Sclerosis (ALS) Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Summary:
Get latest Market Research Reports on Amyotrophic Lateral Sclerosis (ALS) Treatment . Industry analysis & Market Report on Amyotrophic Lateral Sclerosis (ALS) Treatment is a syndicated market report, published as Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.